How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Chemicals and Materials · Forecast 2027–2033
2-Amino-3,5-Dibromopyridine Market
- By Application: Pharmaceutical Intermediates, Agrochemical Intermediates, Dye and Pigment Synthesis, Specialty Chemical Manufacturing, Research and Development
- By Purity Grade: Technical Grade, Reagent Grade, Pharmaceutical Grade, Analytical Grade
- By Form: Powder, Crystalline, Solution
- By End-Use Industry: Pharmaceuticals, Agriculture, Chemical Manufacturing, Biotechnology
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Pharmaceutical Intermediates leads By Application at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 274 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.163 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.171 →
Full report · locked preview
Everything inside the 2-Amino-3,5-Dibromopyridine Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Application 5
Purity Grade 4
Form 3
End-Use Industry 4
Companies profiled
BOC Sciences
Combi-Blocks
AstaTech
Capot Chemical
Merck
Biosynth Carbosynth
Glentham Life Sciences
Alichem
Boroncore
Oakwood Products
Win-Win Chemical
Hairui Chemical
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →BOC Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Combi-Blocks
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →AstaTech
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Capot Chemical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Merck
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Biosynth Carbosynth
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Glentham Life Sciences
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Alichem
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Boroncore
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Oakwood Products
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Win-Win Chemical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Hairui Chemical
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Iodochem
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Thermo Fisher Scientific
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Tokyo Chemical Industry (TCI)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Accela ChemBio
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$10,207M by 2033 · 8.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Pharmaceutical Intermediates56.5
- Agrochemical Intermediates16.0
- Dye and Pigment Synthesis7.3
- Specialty Chemical Manufacturing12.0
- Research and Development8.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,717M → $3,402M · 8.9%
Europe$1,197M → $2,471M · 9.5%
Asia Pacific$1,093M → $2,095M · 8.5%
Latin America$676.4M → $1,489M · 10.4%
Middle East and Africa$520.3M → $1,090M · 9.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.732026
8.762027
8.762028
8.772029
8.792030
8.792031
8.802032
8.822033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- BOC Sciences27.3
- Combi-Blocks10.8
- AstaTech4.7
- Capot Chemical11.5
- Merck12.9
- Biosynth Carbosynth4.9
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Application21.1%
Purity Grade33.5%
Form22.8%
End-Use Industry22.6%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe23.4
- Asia Pacific19.9
- Latin America14.1
- Middle East and Africa10.3
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| BOC Sciences | 79 | 86 | 98 | 80 | 85 | 96 | 87 |
| Combi-Blocks | 78 | 89 | 86 | 93 | 73 | 70 | 82 |
| AstaTech | 67 | 67 | 74 | 82 | 79 | 73 | 74 |
| Capot Chemical | 82 | 81 | 78 | 59 | 66 | 61 | 71 |
| Merck | 75 | 54 | 61 | 61 | 70 | 55 | 63 |
| Biosynth Carbosynth | 54 | 61 | 50 | 57 | 57 | 64 | 57 |
| Glentham Life Sciences | 53 | 61 | 51 | 62 | 46 | 42 | 53 |
| Alichem | 41 | 37 | 45 | 36 | 47 | 47 | 42 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- BOC Sciences
- Combi-Blocks
- AstaTech
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| BOC Sciences | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Combi-Blocks | ✓ | ◐ | ◐ | ✓ | ✓ | ◐ |
| AstaTech | ◐ | ✓ | ◐ | ◐ | ◐ | ✓ |
| Capot Chemical | ◐ | ✓ | ✓ | − | ◐ | ◐ |
| Merck | ◐ | − | ◐ | ◐ | − | − |
| Biosynth Carbosynth | − | ✓ | − | − | ◐ | ✓ |
| Glentham Life Sciences | − | − | − | ◐ | − | − |
| Alichem | − | − | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1BOC Sciences87
2Combi-Blocks82
3AstaTech74
4Capot Chemical71
5Merck63
6Biosynth Carbosynth57
7Glentham Life Sciences53
8Alichem42
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
BOC SciencesCombi-Blocks
Challenger2
Strong scale, closing on the leaders.
AstaTechCapot Chemical
Contender2
Focused players with pockets of strength.
MerckBiosynth Carbosynth
Niche2
Specialists in a single segment or region.
Glentham Life SciencesAlichem
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Application in North America, then scale across 2-Amino-3,5-Dibromopyridine Market — a $66M beachhead inside a $953M market.
Beachhead (SOM)$66Mobtainable near-term
Serviceable (SAM)$365Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Pharmaceutical Intermediates
Best fit — highest urgency & budget in Application.
Economic buyer76 fit
Agrochemical Intermediates
Strong fit — clear ROI and a fast path to value.
End user68 fit
Dye and Pigment Synthesis
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Application in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Purity Grade & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Form
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel27%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Application leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win 2-Amino-3,5-Dibromopyridine Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified21%
Evaluation11%
Closed-won7%
$19.4KCAC
$88KLTV
4.5:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
2-Amino-3,5-Dibromopyridine Market is a durable-growth opportunity — $2.95B by 2033, compounding at 7.6%.
TAM · 2025$1.64Btoday
TAM · 2033$2.95Bforecast
CAGR7.6%2027–2033
Cumulative$20.2Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.95BTotal addressable market
SAM$1.22BServiceable available market
SOM$236MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →7.6% CAGR
Demand compounds through 2033, outpacing GDP across Application.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Application moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.95BLarge & growingTAM by 2033 at 7.6% CAGR
$1.22BServiceable nowreachable with today’s model
$236MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$2.30BBear4.9% CAGR
$2.95BBase7.6% CAGR
$3.77BBull10.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Purity Grade optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
2-Amino-3,5-Dibromopyridine Market — a $1.44B market by 2033. Plan: grow share from 9.0% to 13.8%.
Market size · 2033$1.44Btotal addressable
Market CAGR9.1%2027–2033
Target share13.8%from 9.0% today
Revenue ambition$199Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 9.0% | 13.8% | Ahead |
| Revenue | $138M | $199M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | At risk |
| Gross margin | 29.1% | 41.3% | Ahead |
| Customer retention | 88.7% | 92.4% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Application
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Purity Grade capability
A defensible second engine — invest in Purity Grade to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Application share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Purity Grade
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $23M capacity & capability investment
- Greenlight bolt-on M&A in Purity Grade
- Authorise North America expansion plan
- Fund R&D program for Application leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeAhead
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the 2-Amino-3,5-Dibromopyridine Market conversation — a $7.57B market you can size, segment and defend in minutes.
Market size · 2033$7.57Btotal opportunity
Growth9.1%CAGR to 2033
Addressable buyers1,761+accounts in scope
Typical ROI7.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Application
Goal Grow share in Application
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →7.3×return on cost, year one
< 3 mopayback period
$56K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
BOC SciencesCombi-BlocksAstaTechCapot ChemicalMerckBiosynth CarbosynthGlentham Life SciencesAlichem+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your 2-Amino-3,5-Dibromopyridine Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
2-Amino-3,5-Dibromopyridine Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Chemicals and Materials · scroll →2-Amino-3-(1H-Imidazol-4-Yl)Propanoic Acid Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View report2-Amino-2-Thiazoline Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View report2-Amino-2-methyl-propanol (AMP) Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View report2-Amino-2-Methylpropane Nitrile Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View report2-Amino-2-Methyl -1-Propanol Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View report2-Amino-2-Ethyl-1,3-Propanediol Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View report2-Amino-1-butanol Market
Market size, share, segmentation and regional forecast.
$5.9B market · 2025 base year
View report2-Amino-1,3-Propanediol Market
Market size, share, segmentation and regional forecast.
$5.8B market · 2025 base year
View report2-Aluminum Chlorohydrate Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View report2-Allylphenol Market
2-Allylphenol Market is valued at USD 18 Million in 2025 and is expected to reach USD 26.4 Mill…
$18M market · 2025 base year
View report2-Acrylamide-2-Methylpropanesulfonic Acid Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View report2-Acrylamide-2-Methylpropanesulfonic Acid (CAS 15214-89-8) Market
Market size, share, segmentation and regional forecast.
$744M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.